Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expenses fell sharply; 2) the rapid release of ensatinib and a solid step in internationalization; 3) the two newly launched products provided increased performance and continued progress in the research pipeline; 4) maintained the growth trend in the first quarter of this year, and EYP-1901 phase II clinical data showed treatment potential. (Mainichi Keizai Shimbun)
长城国瑞证券4月22日发布研报称，给予贝达药业（300558.SZ）买入评级。评级理由主要包括：1）利润端重回增长，管理及财务费用大幅下降；2）恩沙替尼快速放量，国际化踏出坚实一步；3）新上市两款产品提供业绩增量，在研管线持续推进；4）今年一季度保持增长态势，EYP-1901二期临床数据展现治疗潜力。（每日经济新闻）
Great Wall Guorui Securities released a research report on April 22 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side returned to growth, and management and financial expe
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.